<DOC>
	<DOCNO>NCT00118742</DOCNO>
	<brief_summary>This two-arm study ass efficacy safety long-term calcineurin inhibitor-free maintenance regimen CellCept sirolimus recipient orthotropic liver transplant . Patients randomize receive either CellCept 1-1.5 g twice daily ( BID ) + tacrolimus + cyclosporine , CellCept 1-1.5 g BID + sirolimus . The anticipated time study treatment 1 2 year , target sample size 100 500 individual .</brief_summary>
	<brief_title>Liver Spare Nephron ( STN ) Study - A Study CellCept ( Mycophenolate Mofetil ) Sirolimus Recipients Liver Transplant</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Adult patient 1874 year age Single primary liver transplant decease donor CellCept plus tacrolimus cyclosporine time transplantation ( within 72 hour ) Patients hepatitis Cpositive status may enter intraoperative ( back table ) biopsy transplant liver biopsy time randomization . This required patient negative hepatitis C. Liver allograft live donor split liver Multiple organ transplant Dialysis therapy &gt; 14 day transplantation randomization History malignancy last 5 year ( except hepatoma nonmelanoma skin cancer ) Previous sirolimus therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>